Foresight Diagnostics

Foresight Diagnostics is an early-stage molecular diagnostics company that has developed a novel liquid biopsy assay for the measurement of minimal residual disease (MRD) to improve the lives of patients worldwide. Our cell-free DNA liquid biopsy assays are based on a new proprietary method developed at Stanford University. Our approach enables earlier detection of smaller tumors, providing patients with more personalized and effective cancer treatment strategies. We have deep expertise in molecular biology, bioinformatics, and next-generation sequencing.